FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:WNK1-KDM5A

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: WNK1-KDM5A
FusionPDB ID: 99334
FusionGDB2.0 ID: 99334
HgeneTgene
Gene symbol

WNK1

KDM5A

Gene ID

65125

5927

Gene nameWNK lysine deficient protein kinase 1lysine demethylase 5A
SynonymsHSAN2|HSN2|KDP|PPP1R167|PRKWNK1|PSK|p65RBBP-2|RBBP2|RBP2
Cytomap

12p13.33

12p13.33

Type of geneprotein-codingprotein-coding
Descriptionserine/threonine-protein kinase WNK1WNK lysine deficient protein kinase 1 isoformerythrocyte 65 kDa proteinprostate-derived sterile 20-like kinaseprotein kinase with no lysine 1protein phosphatase 1, regulatory subunit 167serine/threonine-protein kilysine-specific demethylase 5AJumonji, AT rich interactive domain 1A (RBP2-like)histone demethylase JARID1Ajumonji/ARID domain-containing protein 1Alysine (K)-specific demethylase 5Aretinoblastoma binding protein 2
Modification date2020032720200313
UniProtAcc.

P29375

Main function of 5'-partner protein: FUNCTION: Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Regulates specific gene transcription through DNA-binding on 5'-CCGCCC-3' motif (PubMed:18270511). May stimulate transcription mediated by nuclear receptors. Involved in transcriptional regulation of Hox proteins during cell differentiation (PubMed:19430464). May participate in transcriptional repression of cytokines such as CXCL12. Plays a role in the regulation of the circadian rhythm and in maintaining the normal periodicity of the circadian clock. In a histone demethylase-independent manner, acts as a coactivator of the CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER1/2 and other clock-controlled genes and increases histone acetylation at PER1/2 promoters by inhibiting the activity of HDAC1 (By similarity). Seems to act as a transcriptional corepressor for some genes such as MT1F and to favor the proliferation of cancer cells (PubMed:27427228). {ECO:0000250|UniProtKB:Q3UXZ9, ECO:0000269|PubMed:11358960, ECO:0000269|PubMed:15949438, ECO:0000269|PubMed:17320160, ECO:0000269|PubMed:17320161, ECO:0000269|PubMed:17320163, ECO:0000269|PubMed:18270511, ECO:0000269|PubMed:19430464, ECO:0000269|PubMed:27427228}.
Ensembl transtripts involved in fusion geneENST idsENST00000540360, ENST00000315939, 
ENST00000530271, ENST00000535572, 
ENST00000537687, ENST00000340908, 
ENST00000447667, ENST00000574564, 
ENST00000399788, ENST00000382815, 
ENST00000540838, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score23 X 19 X 15=655510 X 11 X 4=440
# samples 3710
** MAII scorelog2(37/6555*10)=-4.14699860459281
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(10/440*10)=-2.13750352374993
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: WNK1 [Title/Abstract] AND KDM5A [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: WNK1 [Title/Abstract] AND KDM5A [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)WNK1(939326)-KDM5A(432947), # samples:2
Anticipated loss of major functional domain due to fusion event.WNK1-KDM5A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
WNK1-KDM5A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
WNK1-KDM5A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
WNK1-KDM5A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneWNK1

GO:0006468

protein phosphorylation

10660600

HgeneWNK1

GO:0010923

negative regulation of phosphatase activity

19389623

HgeneWNK1

GO:0023016

signal transduction by trans-phosphorylation

16669787

HgeneWNK1

GO:0035556

intracellular signal transduction

10660600

TgeneKDM5A

GO:0034720

histone H3-K4 demethylation

18270511

TgeneKDM5A

GO:0045893

positive regulation of transcription, DNA-templated

11358960



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:939326/chr12:432947)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across WNK1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across KDM5A (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000535572WNK1chr12939326+ENST00000399788KDM5Achr12432947-10716228482653881520
ENST00000537687WNK1chr12939326+ENST00000399788KDM5Achr12432947-10386195449650581520
ENST00000315939WNK1chr12939326+ENST00000399788KDM5Achr12432947-10386195449650581520
ENST00000530271WNK1chr12939326+ENST00000399788KDM5Achr12432947-97431311044151471

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000535572ENST00000399788WNK1chr12939326+KDM5Achr12432947-0.0002988170.9997012
ENST00000537687ENST00000399788WNK1chr12939326+KDM5Achr12432947-0.0002041530.99979585
ENST00000315939ENST00000399788WNK1chr12939326+KDM5Achr12432947-0.0002041530.99979585
ENST00000530271ENST00000399788WNK1chr12939326+KDM5Achr12432947-8.52E-050.99991477

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for WNK1-KDM5A

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
WNK1chr12939326KDM5Achr124329471311437CQNAAQIYRRVTSGVLMSEEEVFELV
WNK1chr12939326KDM5Achr124329471954486CQNAAQIYRRVTSGVLMSEEEVFELV
WNK1chr12939326KDM5Achr124329472284486CQNAAQIYRRVTSGVLMSEEEVFELV

Top

Potential FusionNeoAntigen Information of WNK1-KDM5A in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
WNK1-KDM5A_939326_432947.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
WNK1-KDM5Achr12939326chr124329471954HLA-B27:04RRVTSGVLM0.99980.8255817
WNK1-KDM5Achr12939326chr124329471954HLA-B27:05RRVTSGVLM0.99980.807817
WNK1-KDM5Achr12939326chr124329471954HLA-B27:02RRVTSGVLM0.99980.5083817
WNK1-KDM5Achr12939326chr124329471954HLA-B39:24YRRVTSGVL0.98360.6704716
WNK1-KDM5Achr12939326chr124329471954HLA-B14:02YRRVTSGVL0.96820.7849716
WNK1-KDM5Achr12939326chr124329471954HLA-B14:01YRRVTSGVL0.96820.7849716
WNK1-KDM5Achr12939326chr124329471954HLA-B15:10YRRVTSGVL0.81810.6981716
WNK1-KDM5Achr12939326chr124329471954HLA-B15:37YRRVTSGVL0.43420.6131716
WNK1-KDM5Achr12939326chr124329471954HLA-B07:10YRRVTSGVL0.28680.6534716
WNK1-KDM5Achr12939326chr124329471954HLA-B07:10RRVTSGVLM0.06140.6939817
WNK1-KDM5Achr12939326chr124329471954HLA-B27:14RRVTSGVLM0.99980.7667817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:95RRVTSGVLM0.99830.6582817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:05RRVTSGVLM0.99630.9115817
WNK1-KDM5Achr12939326chr124329471954HLA-B27:03RRVTSGVLM0.99350.8297817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:27RRVTSGVLM0.99320.9317817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:13RRVTSGVLM0.99290.939817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:29RRVTSGVLM0.99230.8986817
WNK1-KDM5Achr12939326chr124329471954HLA-B39:12RRVTSGVLM0.9590.8075817
WNK1-KDM5Achr12939326chr124329471954HLA-B39:12YRRVTSGVL0.95440.8325716
WNK1-KDM5Achr12939326chr124329471954HLA-C07:05YRRVTSGVL0.93170.8599716
WNK1-KDM5Achr12939326chr124329471954HLA-C07:46RRVTSGVLM0.92840.9049817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:13YRRVTSGVL0.92220.9402716
WNK1-KDM5Achr12939326chr124329471954HLA-C07:27YRRVTSGVL0.91840.8978716
WNK1-KDM5Achr12939326chr124329471954HLA-C07:29YRRVTSGVL0.89980.8864716
WNK1-KDM5Achr12939326chr124329471954HLA-C07:19RRVTSGVLM0.86970.7874817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:80RRVTSGVLM0.84590.9576817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:67RRVTSGVLM0.84590.9576817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:10RRVTSGVLM0.83760.9512817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:46YRRVTSGVL0.64360.908716
WNK1-KDM5Achr12939326chr124329471954HLA-C12:16YRRVTSGVL0.15920.9744716
WNK1-KDM5Achr12939326chr124329471954HLA-C12:16RRVTSGVLM0.07340.9678817
WNK1-KDM5Achr12939326chr124329471954HLA-B27:08RRVTSGVLM0.99980.6998817
WNK1-KDM5Achr12939326chr124329471954HLA-B27:06RRVTSGVLM0.99970.8083817
WNK1-KDM5Achr12939326chr124329471954HLA-B27:10RRVTSGVLM0.99970.9072817
WNK1-KDM5Achr12939326chr124329471954HLA-B27:09RRVTSGVLM0.99910.7544817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:01RRVTSGVLM0.99870.6353817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:17RRVTSGVLM0.98680.9667817
WNK1-KDM5Achr12939326chr124329471954HLA-B27:06YRRVTSGVL0.98450.8275716
WNK1-KDM5Achr12939326chr124329471954HLA-C06:08RRVTSGVLM0.9530.9913817
WNK1-KDM5Achr12939326chr124329471954HLA-B39:31RRVTSGVLM0.9530.8092817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:22RRVTSGVLM0.90240.6531817
WNK1-KDM5Achr12939326chr124329471954HLA-C07:02RRVTSGVLM0.84590.9576817
WNK1-KDM5Achr12939326chr124329471954HLA-C06:08YRRVTSGVL0.83980.9946716
WNK1-KDM5Achr12939326chr124329471954HLA-C07:22YRRVTSGVL0.7490.6406716
WNK1-KDM5Achr12939326chr124329471954HLA-C06:06RRVTSGVLM0.34770.9942817
WNK1-KDM5Achr12939326chr124329471954HLA-C06:17YRRVTSGVL0.18980.9963716
WNK1-KDM5Achr12939326chr124329471954HLA-C06:02YRRVTSGVL0.18980.9963716
WNK1-KDM5Achr12939326chr124329471954HLA-C06:17RRVTSGVLM0.06020.9942817
WNK1-KDM5Achr12939326chr124329471954HLA-C06:02RRVTSGVLM0.06020.9942817
WNK1-KDM5Achr12939326chr124329471954HLA-B27:06YRRVTSGVLM0.99740.7983717

Top

Potential FusionNeoAntigen Information of WNK1-KDM5A in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
WNK1-KDM5A_939326_432947.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
WNK1-KDM5Achr12939326chr124329471954DRB1-0469AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0701AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0701AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0701NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0703AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0703AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0703NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0704AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0705AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0705AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0705NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0706AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0706AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0706NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0707AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0707AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0707NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0708AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0708AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0708NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0709AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0709AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0709NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0711AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0711AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0712AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0712AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0712NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0713AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0713AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0713NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0714AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0714AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0714NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0715AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0715AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0715NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0716AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0716AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0716NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0717AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0717AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0717NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0719AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0719AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-0719NAAQIYRRVTSGVLM217
WNK1-KDM5Achr12939326chr124329471954DRB1-0819AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-0834AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1527AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1534AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1601AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1601AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1602AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1602AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1603AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1603AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1604AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1604AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1605AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1605AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1607AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1607AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1608AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1608AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1609AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1609AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1610AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1610AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1611AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1611AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1612AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1612AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1614AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1614AAQIYRRVTSGVLMS318
WNK1-KDM5Achr12939326chr124329471954DRB1-1616AQIYRRVTSGVLMSE419
WNK1-KDM5Achr12939326chr124329471954DRB1-1616AAQIYRRVTSGVLMS318

Top

Fusion breakpoint peptide structures of WNK1-KDM5A

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
4085IYRRVTSGVLMSEEWNK1KDM5Achr12939326chr124329471954

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of WNK1-KDM5A

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN4085IYRRVTSGVLMSEE-7.15543-7.26883
HLA-B14:023BVN4085IYRRVTSGVLMSEE-4.77435-5.80965
HLA-B52:013W394085IYRRVTSGVLMSEE-6.80875-6.92215
HLA-B52:013W394085IYRRVTSGVLMSEE-4.20386-5.23916
HLA-A11:014UQ24085IYRRVTSGVLMSEE-7.5194-8.5547
HLA-A11:014UQ24085IYRRVTSGVLMSEE-6.9601-7.0735
HLA-A24:025HGA4085IYRRVTSGVLMSEE-7.52403-7.63743
HLA-A24:025HGA4085IYRRVTSGVLMSEE-5.82433-6.85963
HLA-B27:056PYJ4085IYRRVTSGVLMSEE-3.28285-4.31815
HLA-B44:053DX84085IYRRVTSGVLMSEE-5.91172-6.94702
HLA-B44:053DX84085IYRRVTSGVLMSEE-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of WNK1-KDM5A

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
WNK1-KDM5Achr12939326chr12432947716YRRVTSGVLTACCGTCGCGTGACCAGTGGTGTCCTG
WNK1-KDM5Achr12939326chr12432947717YRRVTSGVLMTACCGTCGCGTGACCAGTGGTGTCCTGATG
WNK1-KDM5Achr12939326chr12432947817RRVTSGVLMCGTCGCGTGACCAGTGGTGTCCTGATG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
WNK1-KDM5Achr12939326chr12432947217NAAQIYRRVTSGVLMAATGCTGCACAGATCTACCGTCGCGTGACCAGTGGTGTCCTGATG
WNK1-KDM5Achr12939326chr12432947318AAQIYRRVTSGVLMSGCTGCACAGATCTACCGTCGCGTGACCAGTGGTGTCCTGATGTCA
WNK1-KDM5Achr12939326chr12432947419AQIYRRVTSGVLMSEGCACAGATCTACCGTCGCGTGACCAGTGGTGTCCTGATGTCAGAA

Top

Information of the samples that have these potential fusion neoantigens of WNK1-KDM5A

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCAWNK1-KDM5Achr12939326ENST00000315939chr12432947ENST00000399788TCGA-AN-A0AM-01A

Top

Potential target of CAR-T therapy development for WNK1-KDM5A

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to WNK1-KDM5A

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to WNK1-KDM5A

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource